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ABSTRACT: The first example of an ammonium derivative that causes a specific modification of the active site of type I dehy-
droquinase (DHQ1), a dehydratase enzyme that is a promising target for anti-virulence drug discovery, is described. The resolu-
tion at 1.35 Å of the crystal structure of DHQ1 from Salmonella typhi chemically modified by this ammonium derivative revealed 
that the ligand is covalently attached to the essential Lys170 through the formation of an amine. The detection by mass spectros-
copy of the reaction intermediates, in conjunction with the results of Molecular Dynamics simulations, allowed us to explain the 
inhibition mechanism and the experimentally observed differences between Salmonella typhi and Staphylococcus aureus en-
zymes. The results presented here reveal that the replacement of Phe225 in St-DHQ1 by Tyr214 in Sa-DHQ1 and its hydrogen 
bonding interaction with the conserved water molecule observed in several crystal structures protects the amino adduct against 
further dehydration/aromatization reactions. In contrast, for the St-DHQ1 enzyme, the carboxylate group of Asp114, with the 
assistance of this water molecule, would trigger the formation of a Schiff base that can undergo further dehydration reactions 
until full aromatization of the cyclohexane ring is achieved. Moreover, in vitro anti-virulence studies showed that the reported 
compound is able to reduce the ability of Salmonella Enteritidis to kill A459 respiratory cells. These studies have identified a 
good scaffold for the design of irreversible inhibitors that can be used as drugs and has opened up new opportunities for the 
development of novel anti-virulence agents by targeting the DHQ1 enzyme. 
INTRODUCTION 
The increasing and widespread development of resistance 
to antibiotics has made infectious diseases one of the most 
important public health issues in both community and clini-
cal settings.
1
 The WHO currently considers antibiotic re-
sistance to be one of the three greatest threats to human 
health in the coming decades. Hence, there is great interest 
in the development of alternative therapies, the identifica-
tion of unexplored bacterial targets, and the discovery of new 
strategies for the treatment of infections that are resistant to 
current antibiotics.
2 
The most widely used strategy to combat 
bacterial infections is based on the disruption of their viabil-
ity by preventing the synthesis and assembly of key compo-
nents for bacterial survival, such as cell wall biosynthesis, 
DNA replication, RNA transcription, folate biosynthesis, and 
protein biosynthesis.
3 
Although this strategy is highly effec-
tive and many antibiotics in clinical use are based on this 
principle, it causes substantial stress to the bacterium and 
this favors the growing emergence of antibiotic-resistant 
strains. To avoid this issue, in recent years a great deal of 
effort has been devoted to the development of alternative 
approaches. Targeting bacterial virulence or disrupting the 
interaction between the host and the pathogen are attractive 
choices that are increasingly being explored.
2,4
 Anti-virulence 
drugs will create an in vivo scenario similar to that achieved 
by vaccination with a live attenuated strain. In this context, it 
has been suggested that the type I dehydroquinase enzyme 
(DHQ1, 3-dehydroquinate dehydratase, EC 4.2.1.10), the third 
enzyme in the biosynthesis of aromatic amino acids, may act 
as a virulence factor in vivo as the deletion of the aroD gene, 
which encodes DHQ1 from Salmonella typhi and Shigella 
flexneri, has been proven to afford satisfactory live oral vac-
cines, with the latter providing monkeys with protection 
against oral challenge with live S. flexneri 2457T.
5 
This find-
ing, together with the fact that DHQ1 does not have any 
counterpart in human cells, has pinpointed DHQ1 as a prom-
ising target in the search for new anti-virulence agents to 
combat widespread antibiotic resistance. Hence, there is 
 
great interest in developing efficient inhibitors of this en-
zyme as well as obtaining a detailed knowledge of its mecha-
nism of action for the rational design of inhibitors that can 
be used as drugs. 
DHQ1 is present in plants and several pathogenic bacteria, 
such as Escherichia coli, Salmonella typhi and Staphylococcus 
aureus. DHQ1 is a class I aldolase enzyme that catalyzes the 
reversible syn elimination of water in 3-dehydroquinic acid 
(1) to form 3-dehydroshikimic acid (2) by a multi-step mech-
anism that involves the formation of Schiff base species 
(Scheme 1).
6
 The reaction is initiated by the formation of the 
substrate-Schiff base between the C3 carbonyl group of the 
substrate and an essential lysine (Lys170 in S. typhi). Once 
the substrate-Schiff base has been formed, a base residue of 
the active site removes the pro-R hydrogen at C2 in 1 to af-
ford an enamine, which undergoes acid-catalyzed elimina-
tion of the C1 hydroxyl group  a reaction that is mediated by 
a histidine (His143 in S. typhi) acting as a proton donor. It 
has been suggested that the formation of the substrate-Schiff 
base involves a distortion of the cyclohexane ring to align the 
bond of the pro-R hydrogen at C2 (pseudo-axial) with the π-
orbital of the imine that increases its acidity.
6c,6e-f
 The role in 
the enzymatic mechanism of this histidine has been the 
subject of much controversy. Based on the proximity of 
His143 to the C2 carbon in the crystal of the substrate-Schiff 
base, this essential residue was highlighted as the base that 
removes the pro-R hydrogen at C2.
7
 However, its role as a 
general base appears to be more complex because the H143A 
variant protein is able to slowly transform substrate to prod-
uct and stalls the hydrolytic release of product from the 
active site.
8
 It seems clear that His143 is involved in both the 







Enzymatic conversion of 3-dehydroquinic acid (1) to 3-
dehydroshikimic acid (2) catalyzed by DHQ1.  
It is important to highlight that this enzymatic reaction is 
also catalyzed by the type II dehydroquinase enzyme 
(DHQ2), but by entirely different mechanism and stereo-
chemical courses.
9,10
 In contrast to DHQ1: (a) no covalent 
attachment of the substrate to the enzyme through Schiff 
base formation is involved; (b) the loss of the more acidic 
pro-S hydrogen from C2 in 1 via the formation of an enolate 
intermediate takes place
11
; (c) compounds targeting the 
DHQ2 enzyme would have an influence on bacterial viability 
(antibiotics) rather than bacterial virulence. Considering that 
DHQ2 is essential in Mycobacterium tuberculosis (aroD 
gene) and Helicobacter pylori (aroD/aroQ gene), many inhib-
itors of the DHQ2 enzyme for the development of novel anti-
tubercular antibiotics as well as new drugs for the treatment 
of infectious diseases caused by H. pylori have been de-
scribed.
12
 Those compounds are either analogs of the natural 
substrate
13
 or mimetics of the enolate intermediate
14
 having 
in both cases inhibition potencies in the nanomolar range. 
An ester prodrug approach of those inhibitors proved to 
increase permeability into the mycobacterial cell and optimal 
in vitro activities were obtained.
14
 More recently, in the 
search for drug-like inhibitors, several 3-nitrobenzylgallate-
based analogs have also been described.
15
 However, these 
aromatic derivatives proved to have considerably lower in-
hibitory potencies (micromolar range) probably due to less 
efficient binding interactions with the carboxylate binding 
pocket that seems to be relevant for good binding affinity. 
To date, very few irreversible inhibitors of DHQ1 have 
been reported (Figure 1).
17,18
 Most of these incorporate reac-
tive electrophilic functional groups and have been described 
as racemic mixtures. Among them, we have recently shown 
that chiral epoxide 7, which is a mimetic of the natural sub-
strate with an S configuration at C3, causes the chemical 
modification of the enzyme.
17c
 The resolution of the crystal 
structure of DHQ1 from Salmonella typhi (St-DHQ1) cova-
lently modified by S epoxide 7 revealed the formation after 
several chemical modifications of a stable Schiff base with 
the essential Lys170. Biochemical and computational studies 
on this compound and its epimer, an epoxide with the R 
configuration at C3, provided strong evidence that the en-
zyme appears to be designed to form the substrate-Schiff 
base by activation and correct positioning of the oxygen 
atom of the ketone group in 1 by His143 and subsequent 
nucleophilic attack by Lys170 from the Si face of the ketone 
group. 
 
Figure 1. Irreversible inhibitors of DHQ1, compounds 3−7, 
chemical modification of St-DHQ1 by 7, and target com-
pound 8. 
Based on these initial results, and in the search for irre-
versible inhibitors that do not bear such reactive functional 
groups for use as drugs, we report herein a mimetic of the 
natural substrate, namely ammonium derivative 8, which is 
an irreversible inhibitor of DHQ1 from S. typhi and S. aureus 
 
(Sa-DHQ1). The resolution at 1.35 Å of the crystal structure of 
St-DHQ1 chemically modified by ammonium derivative 8 
revealed that the ligand is covalently attached to the essen-
tial Lys170 by the formation of an amine. The detection by 
mass spectroscopy of the reaction intermediates, as well as 
the results of docking and Molecular Dynamics (MD) simula-
tion studies, allowed us to explain the experimentally ob-
served differences between the two enzymes and to under-
stand the inhibition mechanism. Moreover, the in vitro effi-
cacy of compound 8 to inhibit bacterial virulence was also 
studied. To our knowledge, this is the first example of an 
ammonium derivative that causes the specific modification 
of the active site of a dehydratase enzyme and that it is also a 
promising target for anti-virulence drug discovery. 
RESULTS AND DISCUSSION 
Synthesis of Ammonium Derivative 8. The target com-
pound was prepared from previously reported epoxide 9
16c
 
(Scheme 2). Nucleophilic ring opening of epoxide 9 by 
treatment with sodium azide in the presence of catalytic 
amounts of 15-crown-5 ether and p-nitrobenzoic acid afford-
ed azide 10 in 77% yield. The presence of this acid was key 
for the reaction to proceed. Organic acids with lower pKa 
values, such as benzoic acid, led to lower conversion and 
lower yields. Azide 10 was reduced to the amine by catalytic 
hydrogenolysis with palladium on carbon as the catalyst. 
Purification of the resulting free amine was difficult and, 
consequently, the crude amine was protected with di-tert-
butyl dicarbonate to give Boc-aminoprotected 11. Finally, 
hydrolysis of methyl ester 11 with concomitant removal of the 
protecting groups gave an excellent yield of amino alcohol 8 






Reagents and conditions: a) NaN3, p-NO2C6H4CO2H, 15-
crown-5, DMF, 115 °C; b) i) H2, Pd/C (10%), MeOH, RT. ii) 
Boc2O, Et3N, DMF, RT; c) HCl (0.3 M), 100 °C. 
Inhibitory Activity of 8. Ammonium derivative 8 was 
found to be a time-dependent irreversible inhibitor of the 
two enzymes (Figure 2). The inactivation proved to be more 
efficient for Sa-DHQ1 than for St-DHQ1. Thus, a 210 µM 
concentration of 8 caused 60% inactivation of Sa-DHQ1 vs 
20% of St-DHQ1 after 30 minutes. A level of 60% inacti-
vation of Sa-DHQ1 was also obtained with lower concentra-
tions of 8 (84 µM) after incubation for 3 h. Higher concentra-
tions of 8 (840 µM) provided a barely detectable enzymatic 
activity of Sa-DHQ1 after approximately 15 min. The Ki and 
kinact values of compound 8 against the two enzymes were 
obtained from Kitz-Wilson plots (Figure S1). Ammonium 
derivative 8 showed Ki values of 905 ± 10 µM and 934 ± 40 
µM and kinact values of 5.3 ± 0.1 ms
-1
 and 3.4 ± 0.1 ms
-1
 against 
Sa-DHQ1 and St-DHQ1, respectively. Under the assay 
conditions, the kinetic parameters for St-DHQ1 and Sa-DHQ1 
were Km = 18  3 µM; kcat = 255  12 s
−1
 and Km = 24  3 µM; kcat 






Figure 2. Variation of the enzymatic activity of DHQ1 with 
time without incubation and after incubation with increasing 
amounts of ammonium derivative 8: A) Sa-DHQ1. B) St-
DHQ1. Error bars represent standard deviation calculated for 
three independent experiments. Assay conditions were PPB 
(50 mM, pH 7.2) at 25 °C.  
Detection of Chemical Modifications. The possible 
chemical modification of samples of inactivated enzymes was 
also studied by mass spectrometry (MALDI). Significant 
differences were found in the mass spectra of samples of 
DHQ1 enzymes inactivated by 8 (Figures 3 and S2). The mass 
spectrum of the Sa-DHQ1 enzyme consisted of a peak for the 
unmodified protein (calculated mass 27003) and a second 
peak for a covalently modified protein, corresponding to an 
additional mass of 209 or 211 on separate samples (Figures 3A 
and 3B). For St-DHQ1, in addition to the unmodified protein 
(calculated mass 27655) and the peak for the covalently mod-
ified protein corresponding to an additional mass of 203, a 
third peak corresponding to an additional mass of 132 was 
identified (Figure 3C).  
These results suggest that in both cases the nucleophilic 
substitution of the amino group had taken place (expected 
mass increase of 203). However, further chemical modifica-
tions are likely to occur for the St-DHQ1 enzyme. Reasoning 
that the peak corresponding to an additional mass of 132 
could be due to subsequent dehydration of the initial adduct 
triggered by the formation of a Schiff base as for epoxide 7, 
samples first incubated with ammonium derivative 8 for 1 h 
were subsequently treated with sodium borohydride and 
analyzed by MALDI. The resulting mass spectrum corrobo-
rated this hypothesis and the corresponding reduced form of 
the chemically modified St-DHQ1 enzyme was observed 
(Figure 3D). It is important to highlight that significant dif-
ferences were not observed for inactivated Sa-DHQ1 samples 
treated with sodium borohydride. In an effort to gain a fur-
 
ther insight into the inhibition mechanism of ammonium 
derivative 8 and to understand the experimentally observed 
differences between the S. aureus and S. typhi enzymes, 
structural and MD simulation studies were carried out. The 
results of these studies are discussed below. 
 
Figure 3. MALDI spectra of samples of DHQ1 chemically 
modified by 8. A) Sa-DHQ1 chemically modified by 8 (420 
µM). B) Sa-DHQ1 chemically modified by 7 (840 µM). C) St-
DHQ1 chemically modified by 8 (420 µM). D) St-DHQ1 
chemically modified by 8 (420 µM) and subsequent treat-
ment with sodium borohydride. Assay conditions were PPB 
(50 mM, pH 7.2) at 25 °C. 
X-ray Crystal Structure of the St-DHQ1/8 Adduct. The 
crystal structure of St-DHQ1 covalently modified by its inhib-
itor 8 was obtained by soaking apo-St-DHQ1 crystals and the 
structure was solved at 1.35 Å (Figure 4). Crystals were 
mounted into cryoloops and were directly flash frozen by 
rapid immersion in liquid nitrogen. X-ray diffraction data 
were collected from crystals cryo-cooled in a stream of cold 
nitrogen gas (100 K) at ambient pressure using synchrotron 
radiation and the data were subsequently processed. The 
structure was determined by molecular replacement, using 
the previously described structure of the reduced form of the 
St-DHQ1 product-Schiff base intermediate (PDB entry 
1QFE
8c
), as a search model and the structure was refined. A 
summary of the statistical data following data reduction and 
processing is given in Table 1. 
Unbiased, calculated electron density maps showed clear 
electron density for the enzyme-modified inhibitor molecule 
8 (Figure 4A). The reported crystal structure shows that the 
ligand is covalently attached to Lys170 by an amine and the 
substrate-covering loop is in the closed conformation. In 
contrast to the previously reported St-DHQ1/7 adduct (PDB 
entry 4CLM
17c
), dehydration of the C3 hydroxyl group did not 
take place as clear electron density was observed for this 
hydroxyl group (Figure S3). It is worth highlighting that this 
structure was obtained by soaking whereas the previous one 
was obtained by co-crystallization after several weeks. In 
addition, the Lys170 side chain is now ordered and the C3 
hydroxyl group establishes a strong hydrogen bonding inter-
action with a water molecule (W134) that is found in several 
crystal structures forming a bridge between Arg82 and the C1 
hydroxyl group. As in PDB entry 4CLM and in the Michaelis 
complex,
17c
 the modified ligand 7 binds to the active site by a 
salt-bridge between its carboxylate group and the guanidini-
um group of the conserved Arg213, which has previously been 
identified by chemical modification as the key residue for 
carboxylate recognition,
10
 and by a bidentate hydrogen bond 
between the carboxylate group of the conserved Glu46 and 
the C4 and C5 hydroxyl groups of the ligand (Figure 4B). The 
ligand is also anchored to the active site by several strong 
hydrogen bonding interactions, which include two residues 
that are located in the substrate-covering loop, Gln231 and 
Ser232, Arg48, His143 and Ser21, and with Arg82 and Asp114 
via two water molecules (W134 and W44, respectively). 
Moreover, the cyclohexane ring of the ligand is located on 
top of the Phe225 through the formation of key CH-π inter-
actions. This residue, which is embedded into an apolar 
pocket involving Ile201, Val139, Leu78 and Ala223, seems to 
act as a ‘bottom lid’ of the active site to isolate this part of the 
active site from the solvent environment and it also blocks 
one of the faces of the substrate for catalysis.  
Table 1. Crystallographic data collection and refinement 






space group I 2 
cell parameters (a, b, c, β), Å, ◦ a = 67.40, b = 42.33, c = 
84.83, β = 105.13 
wavelength (Å) 0.97996 










multiplicity 3.6 (3.6) 
completeness 0.993 (0.993) 




resolution range (Å) 37.63 – 1.35 (1.42 – 1.35) 
reflections used in refinement
c
 48464 (7025) 
reflections used for Rfree 2060 (315) 
R factor
e
 0.174 (0.197) 
Rfree
f
 0.214 (0.264) 
rmsd (bonds (Å)/angles (°)) 0.010/1.5 


















No sigma cut-off or other re-
strictions were used for inclusion of reflections. 
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Values in 
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cording to the program MOLPROBITY.
31
 The percentages 
indicated are for residues in favored and total allowed re-
gions, respectively.  
MD simulation studies were conducted in order to obtain 
further details on the binding mode of the ligand in the St-
DHQ1/8 adduct and to gain an insight into the differences 
observed between the two enzymes. Considering that the 
covalent attachment of the reaction product molecule (as 
reduced from) to the DHQ1 from Escherichia coli causes a 
dramatic increase in the stability of the protein against pro-
teolysis,
8c
 a similar behavior would be expected for the re-
ported chemical modified St-DHQ1 enzyme. 
 
 
Figure 4. Crystal structure of St-DHQ1 covalently modified 
by ammonium derivative 8. A) Unbiased electron density for 
the modified inhibitor 8 (yellow) and its covalent attachment 
to Lys170 of St-DHQ1 (green). From the model obtained by 
molecular replacement and before inclusion of the inhibitor 
molecule, refinement was performed to obtain unbiased 
density for the inhibitor molecule and other model changes. 
A maximum-likelihood weighted 2Fo – Fc map contoured at 
1σ is shown up to 1.6 Å around the inhibitor molecule and Lys 
side chain (red). The final model, including the inhibitor 
molecule, is superimposed onto the map. B) Interactions of 
the modified inhibitor 8 with St-DHQ1 (gray). Hydrogen 
bonding and electrostatic interactions (red) between the 
ligand and St-DHQ1 are shown. Relevant residues are shown 
and labeled. 
Covalent Modification Mechanism. Firstly, the protona-
tion state of the essential His143 and Lys170 in the reported 
crystal structure was studied. The monomer structure in 
aqueous solution using the molecular mechanics force field 
AMBER was employed. Four possibilities were considered, 
i.e. a dual (δ and ε) and a single (δ) protonation state of 
His143, and free and protonated forms of Lys170 (Figures 5 
and S4). Analysis of the variation of the distances involving 
the NZ atom of Lys170 and the NE2 atom of His143, the OD2 
atom of Asp114 and the oxygen atom of WAT44 during 50 ns 
of dynamic simulation and comparison with the reported 
crystal structure clearly showed that in the reported crystal 
structure His143 is protonated in the δ position and the 
Lys170 is in its protonated form. In this arrangement, the 
His143 side chain, the carboxylate group of Asp114 and W44 
are in close contact with the NZ atom of Lys170.  
 
Figure 5. A) Comparison of the binding mode of the ligand 
in the St-DHQ1/8 adduct after minimization and prior to 
simulation (gray) and after 50 ns of dynamic simulation 
(light orange). The protonated forms of Lys170 and His143 
(ND1) are considered. Relevant side chain residues are shown 
and labeled. B) Variation of the distances involving the NZ 
atom of Lys170 and the NE2 atom of His143, the OD2 atom of 
Asp114 and the oxygen atom of W44 during the whole simu-
lation. The protonated forms of Lys170 and His143 (δ) were 
considered. 
Previously reported biochemical and computational stud-
ies on the substrate-Schiff base formation pinpointed His143 
as the residue involved in the deprotonation of the initial 
adduct resulting from nucleophilic attack of the ɛ-amino 
group of Lys170 to the C3 ketone group of the natural sub-
strate.
19
 Similarly, covalent attachment of 8 would probably 
occur by nucleophilic attack of Lys170 with the release of 
ammonia and by activation from the opposite site of the 
histidine acting as a Lewis acid (Figure 6D, path a). An analy-
sis of enzymatic activity of DHQ1 after incubation with com-
pound 8 at different pH values (5.8, 7.0 and 8.0) revealed that 
the enzyme inactivation is less efficient at high pH (Figure 
S11). This pH conditions would reduce the amount of proto-
nated amino group in 8, which is required as leaving group. 
Moreover, an intramolecular cyclization of 8 to afford epox-
ide 7
17c
 followed by epoxide opening by the ɛ-amino group of 
Lys170 might be considered (Figure 6D, path b). The spectro-
scopic monitoring of the possible formation of epoxide 7 
from ammonium derivative 8 in solution at different pH 
conditions reveal that this process does not occur in the 
absence of enzyme (Figures S12 and S13). However, consider-
ing that DHQ1 active site is largely shielded from the solvent 
environment for catalysis,
20
 the reactive side chain residues 
and ligands are likely to be desolvated and a high effective 
concentration of a nucleophile would be therefore achieved. 
It might be then also possible that the ammonium derivative 
8 undergoes an intramolecular cyclization to give epoxide 7 
in the active site. Both pathways would afford the experimen-
tally observed adduct 12.  
The close proximity of the His143 side chain (Figure 5) and 
previous computational studies with the natural sub-
strate,
19,20
 suggests that it might also deprotonate adduct 12 
to afford intermediate I (Figure 6D). MD simulation studies 
performed on intermediate I revealed that most of the time 
W44 remains fixed between the side chain of Asp114 and 
Glu46, with one of its protons engaged in a hydrogen bond 
with a carboxylate oxygen of Asp114 and one of its oxygen’s 
lone pairs pointing towards the external methylene group of 
the ligand (Figures 6A, S5 and S6). This water molecule is 
also in close contact with the guanidinium group of Arg48. In 
addition, the resulting dual-protonated His143 also continues 
 
to interact by hydrogen bonding with the C3 hydroxyl group 
of the ligand. 
 
 
Figure 6. Proposed covalent modification mechanism (D) and representative snapshots of adduct I in St-DHQ1 (A) and Sa-
DHQ1 (B) and plausible disposition of inhibitor 8 for covalent modification by an essential lysine (C, Sa-DHQ1) obtained by MD 
simulation studies. Relevant residues and the water molecule are indicated and labeled. Hydrogen bonds (red) are shown. 
In this arrangement, the carboxylate group of Asp114 might 
be able to remove one of the protons of W44 to afford a 
hydroxide anion, which would be stabilized by the guani-
dinium group of Arg48. This hydroxide anion might then 
remove one of the hydrogen atoms of the methylene group of 
the ligand to trigger the dehydration of the C3 hydroxyl 
group, which would be assisted by His143 as a proton donor. 
A concerted mechanism might also be possible. As a result, 
enamine II, which is in equilibrium with its Schiff base 13, 
would be obtained. The crystal structure of the latter adduct, 
which was obtained by co-crystallization of St-DHQ1 with 
epoxide 7 after several weeks, has previously been solved.
17c
 
For St-DHQ1, the experimentally observed low mass peak 
(additional mass of 132) might be explained by aromatization 
of the resulting enamine II to give Schiff base IV (calculated 
mass increase of 131). The reduction of IV with sodium boro-
hydride would afford amine/ammonium adduct V (calculat-
ed mass increase of 133). 
For Sa-DHQ1, the mass spectrometry data indicate that a 




modified by the formation of an amine. In an effort to ex-
plain these clear differences between the two enzymes, MD 
simulation studies were also performed with the S. aureus 
enzyme. The corresponding Sa-DHQ1/8 adduct was modeled 
using the enzyme coordinates found in the crystal structure 
of the reduced form of the Sa-DHQ1 product-Schiff base 
intermediate (PDB entry 1SFJ
8c
) (see Experimental section). 
Four possibilities were considered for St-DHQ1/7, i.e., a dual 
(δ and ε) and a single (δ) protonation state for His133 and 
free and protonated forms of Lys160 (Figure S7). In addition 
to the fact that the DHQ1 active site is highly conserved, 
comparison of the amino acid sequence in several DHQ1 
enzymes revealed that Phe225 is replaced by a tyrosine 
(Tyr214) in Sa-DHQ1 (Figure S10). In contrast to St-DHQ1, in 
which the cyclohexane ring of the ligand is located on top of 
Phe225 by establishing key CH-π interactions with the axial 
hydrogens of the ring, in Sa-DHQ1 such interactions are only 
observed with the axial C2 hydrogen. The phenol ring of 
Tyr214 is shifted by around 2 Å towards the essential lysine 
binding pocket. In this arrangement, for intermediate I, the 
water molecule (W44 in St-DHQ1) interacts by hydrogen 
bonding with the phenolic group of Tyr124, the carboxylate 
group of the conserved Glu35 and the side chain of Thr68 
(Figures 6B, S8 and S9). More importantly, the carboxylate 
group of Asp102 (Asp114 in S. typhi) is located far away from 
this water molecule and its position remains fixed by the 
guanidinium group of Arg70 (Arg48 in S. typhi) and the side 
chain of Ser131 throughout the whole simulation. Bearing in 
mind that (a) the carboxylate group of the conserved Glu35 
(Glu46 in S. typhi) is mainly involved in a bidentate hydrogen 
bond with the C4 and C5 hydroxyl groups of the ligand and 
(b) the arrangement of this water molecule and Asp102 
throughout the whole simulation, we considered that, for Sa-
DHQ1, amino adduct I would be stable against dehydration, 
as observed experimentally. In contrast, the replacement of 
Tyr214 by Phe225 in St-DHQ1 causes changes in the position 
of the water molecule and its binding interactions that favor 
the elimination reaction (Figures S6 vs S9). These structural 
differences between the two enzymes might explain the 
differences obtained in the mass spectra. Moreover, compu-
tational studies on the binary complex DHQ1/8, initially 
modelled by molecular docking, using the program GOLD 
5.2
21
 followed by MD simulation studies suggest that, for 
both enzymes, the direct covalent linkage of the ammonium 
derivative 8 to the enzyme (Figure 6D, path a) would occur 
by nucleophilic attack of the lysine with the release of am-
monia and by activation from the opposite site of the histi-
dine acting as a Lewis acid (Figure 6C). 
In vitro Anti-virulence Studies. An experimental model 
of infection of A549 human alveolar epithelial cells was used 
to study the efficacy of compound 8 to inhibit the virulence 
of Salmanella Enteritidis. This was carried out by measuring 
the viability of A549 respiratory alveolar cells after infection 
using LIVE/DEAD staining. The mortality rates of alveolar 
cells incubated with the bacterial strain were determined and 
are showed in Figure 7. Coincubation of the Salmonella En-
teritidis clinical strain with the A549 cells resulted in a 37.1% 
decrease in A549 cell viability. Coincubation of the A549 cells 
with the bacteria in presence of 2 and 20 mg L
−1
 incremented 
the viability, showing 19.8% and 13.1% of cell death, respec-
tively. Cells incubated only with compound 8 showed a simi-
lar viability than those not infected (less than 10% of deads 
cells), which reveals not toxic effects to the used concentra-
tions. Thus, the addiction of ammonium derivative 8 to the 
medium reduced the ability of Salmonella Enteritidis to kill 
A549 respiratory cells compared to the control infection (P < 
0.05). 
 
Figure 7. Efficacy of ammonium derivative 8 to inhibit the 
cell death of A549 alveolar cells by Salmonella Enteritidis 
infection. (A) Fluorescence microscopy images of human 
alveolar A549 cells infected with Salmonella Enteritidis clini-
cal strain and stained with the LIVE/DEAD Cellstain double-
staining kit. Stained green cells are healthy cells with intact 
membranes, and dead cells are stained red. A549 cells were 
incubated with Salmonella Enteritidis strain without com-
pound 8 (1); with 2 mg L
−1
 of 8 (2); with 20 mg L
−1
 of 8 (3); 
and last, uninfected cells (4). (B) Quantification of A549 cell 
death caused by Salmonella Enteritidis. The results of four 
independent experiments are shown as means and SD. P < 
0.05 between the treated and untreated cells. 
CONCLUSIONS AND FINAL REMARKS 
The first example of the chemical modification of the es-
sential lysine active site of a dehydratase enzyme (DHQ1) by 
an ammonium derivative that does not bear reactive electro-




DHQ1 from Salmonella typhi and Staphylococcus aureus, 
which are involved in bacterial virulence, has been studied by 
a combination of biochemical, structural and MD simulation 
studies. The resolution at 1.35 Å of the crystal structure of the 
Salmonella typhi DHQ1 enzyme covalently modified by am-
monium derivative 8, which was obtained by soaking apo-St-
DHQ1 crystals, revealed that the modified ligand is covalent-
ly attached to the essential Lys170 through the formation of 
an amine. 
The results of inhibition studies and analysis by mass spec-
trometry of samples of inactivated enzymes showed clear 
differences between the two enzymes. The inactivation 
proved to be more efficient for S. aureus than for S. typhi. 
The results of this study provide strong evidence that the 
initial amine adduct of the St-DHQ1 enzyme undergoes fur-
ther dehydration reactions involving Schiff base species, as 
evidenced by the mass spectra of samples treated with sodi-
um borohydride. The covalent linkage between ammonium 
derivative 8 and DHQ1 would occur either by nucleophilic 
attack of the lysine with the release of ammonia and by acti-
vation from the opposite site of the histidine acting as a 
Lewis acid or via generation of the also irreversible inhibitor 
epoxide 7 by intramolecular cyclization of 8 in the DHQ1 
active site and subsequent nucleophilic attack of the lysine. 
In the latter case, compound 8 would be a prodrug of epox-
ide 7. Further experiments would be required to clarify this 
point. 
The results of computational studies revealed that the re-
placement of Phe225 in St-DHQ1 by Tyr214 in Sa-DHQ1 and 
its hydrogen bonding interaction with the conserved water 
molecule, which has been observed in several crystal struc-
tures and is located in close contact to the NZ atom of the 
essential lysine, would prevent the initial amino adduct from 
undergoing dehydration/aromatization reactions. In con-
trast, for the St-DHQ1 enzyme this water molecule remains 
fixed between the side chain of the conserved Asp114 and 
Glu46 residues. In this arrangement, Asp114, with the assis-
tance of the aforementioned water molecule, would be the 
base that triggers the dehydration of the C3 hydroxyl group 
with His143 acting as a proton donor. As a result, a Schiff 
base will be obtained that can undergo further dehydration 
reactions until full aromatization of the cyclohexane ring is 
achieved.  
Anti-virulence studies also showed that ammonium deriv-
ative 8 is able to reduce the ability of Salmonella Enteritidis 
to kill A549 respiratory cells in vitro. 
The results presented here enhance our understanding of 
some of the determinants for the irreversible inhibition of 
this challenging multistep enzyme. These studies also show 
that the ammonium derivative 8 could be a good scaffold for 
the design of new inhibitors that can be used as drugs and 
opens up new opportunities for the development of novel 
anti-virulence agents to combat widespread antibiotic re-
sistance by targeting the DHQ1 enzyme. 
EXPERIMENTAL SECTION 
General. All starting materials and reagents were com-
mercially available and were used without further purifica-
tion. 
1
H NMR spectra (250 and 500 MHz) and 
13
C NMR spec-
tra (63 and 125 MHz) were measured in deuterated solvents. J 
values are given in Hertz. NMR assignments were carried out 
by a combination of 1 D, COSY, and DEPT-135 experiments. 
FT-IR spectra were recorded as NaCl plates or KBr discs. 
[α]D






. MilliQ deionized 
water was used in all the buffers. The spectroscopic meas-
urements were made on a Varian Cary 100 UV-Vis spectro-
photometer with a 1 cm pathlength cell fitted with a Peltier 
temperature controller. Protein analysis was performed using 
an Ultraflex III TOF/TOF Bruker mass spectrometer. 
Methyl (1R,3S,4S,5R,6S,7S,9R)-7-azidomethyl-7,9-
dihydroxy-3,4-dimethoxy-3,4-dimethyl-2,5-
dioxabiciclo[4.4.0]decan-9-carboxylate (10). A solution of 
epoxide 9
17c
 (479 mg, 1.44 mmol), sodium azide (1.12 g, 17.31 
mmol), p-nitrobenzoic acid (240 mg, 1.44 mmol) and 15-
crown-5 ether (290 µL, 1.45 mmol) in dry DMF (29 mL) and 
under inert atmosphere was heated at 115 °C for 1.5 h. After 
cooling to room temperature, the reaction mixture was dilut-
ed with ethyl acetate and water. The aqueous layer was sepa-
rated and the organic layer was washed with brine, dried 
(anh. Na2SO4), filtered and concentrated under reduced 
pressure. Azide 10 (417 mg, 77%) was obtained as colorless 
oil. [α]D
20 = + 114◦ (c 3.7, CHCl3). 
1
H NMR (250 MHz, CDCl3) δ: 
4.25 (m, 1H, H1), 3.79 (s, 3H, OCH3), 3.67 (s, 1H, OH), 3.58 (d, 
J = 10.0 Hz, 1H, H6), 3.50 (d, J = 12.2 Hz, 1H, CHHN3), 3.30 (d, 
J = 12.2 Hz, 1H, CHHN3), 3.25 (s, 3H, OCH3), 3.24 (s, 3H, 
OCH3), 2.03 (m, 3H, CH2-10+H8eq), 1.91 (d, J = 12.2 Hz, 1H, 
H8ax), 1.33 (s, 3H, CH3) and 1.27 (s, 3H, CH3) ppm. 
13
C NMR 
(63 MHz, CHCl3) δ: 174.4 (C), 100.3 (C), 99.5 (C), 74.9 (C), 
74.4 (C), 72.0 (CH), 63.2 (CH), 55.8 (CH2), 53.2 (OCH3), 48.1 
(OCH3), 47.9 (OCH3), 39.6 (CH2), 38.2 (CH2), 17.7 (CH3) and 
17.7 (CH3) ppm. IR (KBr): υ 3458 (OH), 2104 (N≡N) and 1739 
(CO) cm
−1
. MS (ESI) m/z = 398 (MNa
+
). HRMS calcd for 
C15H25O8N3Na (MNa
+
): 398.1534; found, 398.1537. 
Hydrogenolysis of Azide 10. A suspension of azide 10 
(406 mg, 1.08 mmol) and 10% palladium on carbon (70 mg) 
in methanol (30 mL) was stirred under hydrogen atmosphere 
at room temperature for 1.5 h. The mixture was filtered over 
Celite and the residue was washed with methanol. The 
filtrate and washings were concentrated under reduced 
pressure. The obtained residue was disolved in dry DMF (11 
mL) and treated with dry triethylamine (0.23 mL, 1.62 mmol) 
and di-tert-butyl dicarbonate (280 mg, 1.30 mmol). The 
mixture resulted was stirred at room temperature for 4 h and 
then diluted with ethyl acetate and water. The organic layer 
was separated and the aqueous layer was extracted with ethyl 
acetate (×3). All the organic extracts were dried (anh. 
Na2SO4), filtered and concentrated under reduced pressure. 
The obtained residue was purified by flash chromatography 
on silica gel eluting with ethyl acetate/hexanes [1) (30:70); 2) 
(50:50)] to afford compound 11 (449 mg, 92%). [α]D
20 = + 110◦ 
(c 2.8, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 4.95 (m, 1H, 
NH), 4.23 (m, 1H, H1), 3.76 (s, 3H, OCH3), 3.50 (d, J = 9.9 Hz, 
1H, H6), 3.46 (dd, J = 14.1 and 3.0 Hz, 1H, CHHNH), 3.24 (s, 
3H, OCH3), 3.22 (s, 3H, OCH3), 3.19 (m, 1H, CHHNH), 
2.071.87 (m, 3H, CH2-10+H8eq), 1.85 (d, J = 14.7 Hz, 1H, H8ax), 






C NMR (75 MHz, CDCl3) δ: 174.5 (C), 156.6 (C), 100.2 
(C), 99.4 (C), 79.5 (C(CH3)3), 74.8 (C), 74.2 (C), 74.1 (CH), 
63.4 (CH), 53.1 (OCH3), 48.0 (OCH3), 47.9 (OCH3), 46.7 
(CH2), 39.4 (CH2), 38.3 (CH2), 28.3 (C(CH3)3) 17.7 (CH3) and 
17.7 (CH3) ppm. IR (film): υ 3406 (OH+NH), 1739 (CO) and 
1710 (CO) cm
−1
. MS (ESI) m/z = 472 (MNa
+
). HRMS calcd for 
C20H35NO10Na (MNa
+
): 472.2153; found, 472.2137.  
(1R,3S,4S,5R)-1,3,4,5-tetrahydroxy-3-methylamino-1-
carboxylic acid (hydrochloride form) (8). A solution of 
compound 11b (28 mg, 0.05 mmol) in HCl (0.5 mL, 0.3 M) 
was heated at 100 °C for 1 h. After cooling to room tempera-
ture, the mixture was diluted with water and ethyl acetate. 
The organic layer was separated and the aqueous layer was 
washed with ethyl acetate (×2) and the aqueous extract was 
lyophilized to give amino acid 8 (12.5 mg, 97%) as a beige 
solid. [α]D
20 = – 4◦ (c 1.7, CH3OH). Mp: 148 °C (dec.). 
1
H NMR 
(500 MHz, CD3OD) δ: 3.98 (m, 1H, H5), 3.36 (d, J = 9.0 Hz, 
1H, H4), 3.28 (d, J = 12.5 Hz, 1H, CHHNH3), 2.89 (d, J = 12.5 
Hz, 1H, CHHNH3), 2.20 (ddd, J = 12.0, 4.0 and 2.0 Hz, 1H, 
H6eq), 2.00 (d, J = 12.0 Hz, 1H, H2ax), 1.97 (dd, J = 12.0 and 2.0 
Hz, 1H, H2eq) and 1.81 (dd, J = 12.0 and 13.0 Hz, 1H, H6ax) 
ppm. 
13
C NMR (125 MHz, CD3OD) δ:  175.4 (C), 79.8 (CH), 
76.4 (C), 73.3 (C), 68.4 (CH), 48.5 (CH2), 42.2 (CH2) and 40.1 
(CH2) ppm. IR (KBr): υ 3367 (OH+NH) and 1730 (CO) cm
-1
. 
MS (ESI) m/z = 220 (M–H–HCl). HRMS calcd for C8H14O6 
(M–H–HCl): 220.0827; found, 220.0820. 
Dehydroquinase Assays. The St-DHQ1 and Sa-DHQ1 en-
zymes were purified as described previously.
22,8c
 Concentrat-
ed solutions of St-DHQ1 (0.85 mg mL
−1
, 30.74 µM) and Sa-
DHQ1 (4 mg mL
−1
, 148.13 µM) were stored in potassium 
phosphate buffer (50 mM) and DTT (1 mM) at pH 6.6 and 
80 °C. When required for assays, aliquots of the enzyme 
stocks were diluted in water and buffer and stored on ice.
 
Dehydroquinase was assayed in the forward direction by 
monitoring the increase in absorbance at 234 nm in the UV 
spectrum due to the absorbance of the enone-carboxylate 





000). Standard assay conditions were PPB (50 mM, pH 7.2) at 
25 °C. Each assay was initiated by addition of the substrate. 
Solutions of 3-dehydroquinic acid (1) were calibrated by 
equilibration with DHQ1 and measurement of the change in 
the UV absorbance at 234 nm due to the formation of the 
enone-carboxylate chromophore of 3-dehydroshikimic acid 
(2). Under assay conditions, the kinetic parameters for St-
DHQ1 and Sa-DHQ1 were Km = 24  3 µM; kcat = 1.1  0.1 s
−1 
and Km = 18  3 µM; kcat = 255  12 s
−1
, respectively. Kinetic 
constants were evaluated using the GraFit 5 program (Eritha-
cus Software Ltd.). 
Inhibition Assays. Incubation of St-DHQ1 and Sa-DHQ1 
(2.96 µM from a stock protein concentration of 0.85 mg mL
−1 
and 4 mg mL
−1
, respectively) with various aqueous solutions 
of amino alcohol 8 (42−840 µM) were carried out in PPB (0.5 
mL, 50 mM) at pH 7.2 and 5.8, 25 °C. The activity was pro-
gressively determined over a 24 h period under the standard 
assay conditions (see above) using aliquots from the incuba-
tion samples and the control. 
Sodium Borohydride Inactivations. A 0.5 mL solution 
of St-DHQ1 (50 µL from a stock protein concentration of 0.85 
mg mL
−1
) in PPB (50 mM, pH 7.2) at 25 °C was incubated 
with compound 7 (200 µL from a stock concentration of 2.1 
mM) for 1 h. After this incubation period, greater than 90% 
reduction of the enzyme activity was observed. Under similar 
conditions, DHQ1 was also incubated with the natural sub-
strate as a control. Several aliquots (10 µL) of a solution of 
sodium borohydride (20 mg mL
−1
) in aqueous sodium hy-
droxide (40 mM) were then added. The DHQ1 activity was 
assayed before and after addition of sodium borohydride. 
After the sequential additions of aliquots of sodium borohy-
dride solution (3 × 10 µL), full inactivation was observed for 
those control experiments carried out in the presence of the 
natural substrate. In the absence of the natural substrate or 
compound 8, loss of activity was not observed after treat-
ment with sodium borohydride. The samples were dialyzed 
using Amicon Ultra 0.5 centrifugal filters with 10 kDa cutoff 
by successive addition of aqueous ammonium bicarbonate 
(×4, 5 mM) and concentration. The samples were analyzed by 
mass spectrometry on a MALDI-TOF spectrometer with 
sinapinic acid as matrix. 
Crystallization of the St-DHQ1/8 Adduct. Prism-shaped 
apo-St-DHQ1 crystals of up to 0.03 mm × 0.03 mm were 
obtained from a freshly purified solution of St-DHQ1 concen-
trated to 8 mg mL
–1 
in buffer A (10 mM Tris-HCl pH 7.4, 40 
mM KCl) after 4 weeks of vapor diffusion in sitting drops 
comprised of 2.0 μL of protein solution mixed with 2.0 μL of 
reservoir solution and equilibrated against 0.15 mL reservoirs 
containing the crystallization mixture [25% (w/v) PEG 3350, 
0.1 M Bis-Tris pH 5.5, 0.2 M magnesium chloride]. St-DHQ1/8 
adduct complex crystals were obtained after soaking during 
24 h of apo-St-DHQ1 crystals in 10 mM solutions of ammoni-
um derivative 8 in the crystallization mixture. 
Structure Determination of the St-DHQ1/8 Adduct. 
Crystals were mounted into cryoloops and directly flash 
frozen by rapid immersion in liquid nitrogen. X-ray diffrac-
tion data were collected on beamline BM30A-FIP (ESRF, 
Grenoble, France) from a crystal maintained at 100 K. The 
diffraction data were processed, scaled, corrected for absorp-
tion effects and the crystal unit-cell parameters were calcu-




 and other 
programs within the CCP4 software suite.
25
 The structure 
was solved by molecular replacement, using the program 
MOLREP
26
 with a search model generated from PDB entry 
1QFE.
8c
 The ligand structure and geometrical restraints were 
generated with the PRODRG2
27
 server and the structure was 
manually placed during the model building, which was per-
formed with COOT.
28
 Reflections used to calculate Rfree
29 
were selected randomly. The refinement of the models was 
performed with REFMAC
30 
and final structure validation was 
performed with MOLPROBITY.
31 The data collection, re-
finement and model statistics are summarized in Table 1. 
Structure figures were prepared using PYMOL.
32
  
Molecular Dynamics Simulations. Ligand preparation. 
Lysine bound ligands were capped with the usual acetyl and 
methylamino groups. No bounded ligands were manually 
docked into the active site. Partial charges were derived by 
quantum mechanical calculations (HF/6-31G*) using Gaussi-
an 09,
33






according to the RESP
35
 model. The missing bonded and 
non-bonded parameters were assigned, by analogy or 
through interpolation from those already present in the 
AMBER database (GAFF).
36 
Generation and minimization of the DHQ1-ligand adducts. 
a) St-DHQ1 model: These studies were carried out using the 
enzyme coordinates found in the crystal structure of St-
DHQ1/8 adduct. b) Sa-DHQ1 model: Simulations were car-
ried out using the enzyme coordinates found in the crystal 
structure of the reduced form of the product-Schiff base 
intermediate of Sa-DHQ1 (PDB entry 1SFJ,
8c
 chain A). Un-
solved residues were added by superimposition with other 
chains and crystal structures (PDB entry 1SFL
8c
).  
Crystallographic water molecules were maintained. Hy-
drogens were added and protonation states to all titratable 
residues at the chosen pH of 7.0 were assigned using web-
based H++ (version 3.1),
37
 and WHAT-IF Optimal Hydrogen 
Bonding Network tool.
38
 As a result of this analysis, for Sa-
DHQ1 model, terminal groups of residues Asn25, Gln60, 
His132, Gln221 and Gln225 were rotated 180 degrees. His3, 
His26, His114 and His166 were protonated in ε position, 
His132 in δ position and His120 in both positions (δ and ε). 
For St-DHQ1 model, His51, His96, His146, His179, His194 
were protonated in ε position and His132, His134 and His250 
in both positions. Two protonation states for His143/His133 
(δ or δ and ε) were considered as well as for the amino group 
of the ligand. Molecular mechanics parameters from the 
ff12SB
39
 were assigned to the protein and the ligands using 
the LEaP module of AMBER 12.
40
 Each molecular system was 
immersed in a truncated octahedron containing TIP3P
41
 




 to achieve elec-
troneutrality. 
All systems were minimized in four stages: a) initial mini-
mization of the ligand (and the missing residues in Sa-DHQ1 
model, residues 10−20 and 55−64) applying a restraint mask 
to the rest of the atoms; b) minimization of the solvent and 
ions with a restraint mask to the protein and ligand; c) min-
imization of the side chains, waters and ions by applying a 
restraint mask to all α carbons; d) final minimization of the 





 was used. 1000 steps were used for the first 
minimization and 5000 in the rest, with the first half of them 
using steepest descent method, the second half using conju-
gate gradient method. 
Simulations. MD simulations were performed using the 
pmemd.cuda_SPFP module
43
 in AMBER 14
44
 suite of programs 
and Amber ff12SB force field. Periodic boundary conditions 
were applied and electrostatic interactions were treated 
using the smooth particle mesh Ewald method (PME)
45
 with 
a grid spacing of 1 Å. The cutoff distance for the non-bonded 
interactions was 9 Å. The SHAKE algorithm
46
 was applied to 
all bonds containing hydrogen, using a tolerance of 10
–5
 Å 
and an integration step of 2.0 fs. The minimized system was 
heated at 300 K (1 atm, 200 ps, a positional restraint force 




applied to all α carbons). Follow-
ing equilibration under a constant volume (NVT) ensemble 





applied to all α carbons); and six stages of equilibrations 
under a constant pressure (NPT) ensemble were carried out 
for 100 ps each, reducing gradually the initial force constraint 








in the final stage. MD 
simulations were carried out for 50 ns collecting system 
coordinates every 10 ps for further analysis. 
In vitro Anti-virulence Studies. An experimental model 
of infection of A549 human alveolar epithelial cells was used 
to study the efficacy of compound 8 to inhibit the virulence 
of Salmonella Enteritidis. Cells were cultured in Dulbecco 
modified Eagle medium (DMEM) supplemented with 10% 
fetal bovine serum, 100 mg L
−1
 of penicillin, and 100 mg L
−1
 
streptomycin at 37 °C in the presence of 10% CO2. For cell 
viability assays, monolayers of A549 cells were cultured in 
24-well plates to a density of 10
5
 cells per well. Later, the cells 
were infected with 15 × 10
7
 Colony-Forming Units (CFU) per 
well of a clinical strain of Salmonella Enteritidis isolated in 
the A Coruña Hospital. New DMEM with 2 or 20 mg L
−1
 of 
compound 8 was added to the cells and were grown for 4 h at 
37 °C. Controls without the bacterial infection and without 
inhibitor 8 were used. The number of inoculated bacteria was 
determined by direct plating. A LIVE/DEAD fluorescence 
microscopy kit (Cellstain double-staining kit; Fluka, Buchs, 
Switzerland) was used according to the manufacturer's in-
structions to measure cell viability postinfection. The A549 
cells were incubated for 15 min at 37 °C with phosphate-
buffered saline (PBS) containing a mixture of the two fluo-
rescent molecules to obtain simultaneous fluorescent stain-
ing; calcein-AM, is able to stain viable cells (green), while 
propidium iodide, can stain only dead cells (red). Microscop-
ic images of the stained cells (alive and dead) were obtained 
using an inverted fluorescence microscope (Nikon Eclipse Ti) 
and analyzed with the NIS Elements Br software package.
47
 
At least four replicates of each assay were analyzed, and the 
statistical significance was determined using Student's t test. 
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